Fortress Biotech Inc

Financials

Übersicht Finanzbericht Statistik Dividenden

Mittelzufluss aus laufender Geschäftstätigkeit -83.68 M-116.54 M-179.4 M-128.22 M-80.19 M-65.78 M -65.78 M Mittelzufluss aus Investitionstätigkeit -7.16 M40.51 M-22.93 M-2.1 M-15 M10.12 M 10.12 M Zahlungsströme aus der Finanzierungstätigkeit 172.41 M148.99 M75.32 M32.74 M70.64 M77.44 M 77.44 M Freier Cashflow -86.81 M-121.51 M-182.12 M-133.29 M-95.19 M-65.78 M -65.78 M

Fortress Biotech Inc., commonly known as Fortress Bio, is a biopharmaceutical company that acquires, develops, and commercializes innovative pharmaceutical and biotechnology products. Led by CEO Lindsay A. Rosenwald, M.D., Fortress and most of its subsidiary companies are headquartered in Bay Harbor Islands, Florida.

FBIO

Financials

Fortress Biotech Inc

Nachrichten

Avenue Therapeutics licenses ATX-04 for Pompe disease treatment

Fortress Biotech Stock: The PRV Catalyst That Could Reprice This Microcap (NASDAQ:FBIO)

Cigna Q4 Earnings Beat Estimates on Higher Specialty Volumes

Elevance Health Q4 Earnings Beat Estimates on Increasing Premiums

Centene Expands Palliative Care Access in Ohio Through Tuesday Health

FDA erteilt Zulassung für erste Therapie gegen Menkes-Syndrom bei Kindern

FDA approves first treatment for Menkes disease in children

FDA setzt neuen PDUFA-Termin für Menkes-Therapie von Fortress Biotech fest

FDA sets new PDUFA date for Fortress Biotech’s Menkes disease therapy

Fortress Biotech (FBIO) Surpasses Q3 Earnings Estimates

Fortress Biotech, Inc. (FBIO) Q3 2025 Earnings Call Transcript

Journey Medical meldet für Q3 2025 Umsatzsprung und strategisches Wachstum